October 17
Genovese MC, Kremer JM, van Vollenhoven RF, Alten R, Scali JJ, Kelman A, Dimonaco S, Brockwell L.
Arthritis Rheumatol. 2017 Sep;69(9):1751-1761. doi: 10.1002/art.40176
In this pooled analysis investigating liver enzyme abnormalities and hepatic adverse events (AEs) during long-term tocilizumab (TCZ) treatment for RA in clinical trials, although transaminase elevations were frequent, rates of hepatic serious AEs remained low. Data were pooled from patients who received ≥1 dose of IV TCZ with or without DMARDs in Phase 3 or 4 clinical trials, long-term extensions, and a pharmacology study. A total of 4171 patients were included in the all-exposure populati...
Keywords: IL-6, Tocilizumab, Clinical, Safety
Translated by: Igor Kos